🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Eyestem Research bags $10 Mn in Series B round

EntrackrEntrackr · 2d ago
Eyestem Research bags $10 Mn in Series B round
Medial

Eyestem Research bags $10 Mn in Series B round Clinical-stage biotechnology company Eyestem Research has raised $10 million in a Series B funding round co-led by Raju Barwale and Alkem Laboratories managing director Sandeep Singh. The Bengaluru-based company had previously raised $9.95 million from Alkem Lab., Biological E, and C-CAMP. The proceeds will be utilized for the completion of the ongoing Phase 2 clinical trial in India and support preparations for filing an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA), Eyestem said in a press release. Co-founded in 2015 by Jogin Desai, Rajani Battu, and Rajarshi Pal, Eyestem Research focuses on developing cell replacement therapies for incurable eye diseases. The company is known for its work on dry age-related macular degeneration (AMD). It is developing a therapy called Eyecyte-RPE, which uses retinal pigment epithelium (RPE) cells derived from human-induced pluripotent stem cells to replace damaged cells in the retina. According to Eyestem, Eyecyte-RPE is being developed for patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD). The company has submitted its Phase 1 clinical study report to the Central Drugs Standard Control Organisation (CDSCO) and is awaiting approval to initiate Phase 2. As per the company, Eyecyte-RPE can help replace the damaged or lost retinal pigment epithelial (RPE) cells and potentially enable tissue regeneration in the diseased retina. This unique formulation is allogeneic, scalable, and can be stored as a frozen vial for long periods of time. Dry AMD is the leading cause of blindness for people over 50. Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that leads to progressive and irreversible loss of central vision, characterized by the death of cells in the macula, the central part of the retina. Approximately 196 million people suffer from dry AMD globally, five million of whom suffer from GA. The other notable players in this space are Lineage Cell Therapeutics and Voyager Therapeutics.

Speech therapy startup Iyaso secures pre-seed funding

EntrackrEntrackr · 4m ago
Speech therapy startup Iyaso secures pre-seed funding
Medial

Speech therapy startup Iyaso secures pre-seed funding Speech therapy company Iyaso has raised $500K in a pre-seed funding round led by Malpani Ventures, along with participation from several angel investors. The proceeds will be used to develop novel and innovative AI-powered digital therapeutics that redefine how speech and communication challenges are treated worldwide, Iyaso said in a press release. Founded in 2023 by Viraj Kulkarni, Iyaso is an AI-powered platform offering solutions for speech therapy. It aims to help users overcome stuttering through speech therapy and provides a guided program to enhance fluency and develop a positive attitude toward speaking. The platform aspires to empower speech therapy using AI to make it more effective, engaging, and accessible than ever before. According to market research, over 400 million people worldwide struggle with speech and language disorders, which directly impact their academics, careers, and social interactions. According to the Pune-based company, it has developed structured and personalized interventions to help users learn, practice, and apply speech therapy techniques in real-world situations. Iyaso states that its first product, Eloquent for Stuttering, has been used by more than 20,000 users across over 150 countries since its launch in July 2024. Eloquent helps people who stutter improve fluency and confidence through AI-driven exercises and immersive practice simulations. Early validation studies show a 53% reduction in stuttering severity and a 34% improvement in communication confidence, with more than 75% of participants moving to a lower stuttering severity category after using it.

Download the medial app to read full posts, comements and news.